IP Library › Patent Application 18484185

Patent Application

App. No. 18/484,185

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 18/484,185

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Claims (59)

1 .- 15 . (canceled)

16 . A method of preparing a compound of Formula (I):

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprising

coupling the NH group of Ring C and the Q b group of Ring B of a compound of Formula (Y-I):

a salt thereof, or a deuterated derivative of any of the foregoing, wherein:

Q b is a halogen;

Ring A is a phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;

Ring B is a pyridinyl ring;

Ring D is a phenyl ring, a 5-membered heterocyclyl ring, a 6-membered heterocyclyl ring, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring;

X is O, NH, or an N(C 1 -C 4 alkyl);

each R 1 is independently chosen from C 1 -C 2 alkyl groups, C 1 -C 2 alkoxyl groups, C 1 -C 2 haloalkyl groups, C 1 -C 2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;

m is 0, 1, 2, 3, or 4;

each R 2 is independently chosen from C 1 -C 2 alkyl groups, C 1 -C 2 alkoxyl groups, C 1 -C 2 haloalkyl groups, C 1 -C 2 haloalkoxyl groups, halogens, a cyano group, and a hydroxyl group;

n is 0, 1, or 2;

each R 3 is methyl;

each R 4 is independently chosen from halogens, an oxo group, a hydroxyl group, a cyano group, and —(Y) k —R 7 groups, or optionally two R 4 , together with the atom(s) they are attached to, form a 5-6 membered cycloalkyl or heterocyclyl ring that is optionally and independently substituted with one or more groups chosen from halogens, C 1 -C 2 alkyl groups, haloalkyl groups, a hydroxyl group, C 1 -C 2 alkoxyl groups, and C 1 -C 2 haloalkoxyl groups; wherein:

k is 0, 1, 2, 3, 4, 5, or 6;

each Y is independently chosen from C(R 5 )(R 6 ) groups, —O—, and —NR a — groups, wherein a heteroatom in —(Y) k —R 7 is not bonded to another heteroatom in —(Y) k —R 7 , wherein:

each R 5 and R 6 is independently chosen from hydrogen, halogens, a hydroxyl group, C 1 -C 4 alkyl groups, and C 3-5 cycloalkyl groups, or R 5 and R 6 on the same carbon together form a C 3-5 cycloalkyl group or oxo;

each of R 5 and R 6 is optionally independently substituted with one or more groups chosen from C 1 -C 2 alkyl groups, C 1 -C 2 haloalkyl groups, halogens, a hydroxyl group, C 1 -C 2 alkoxyl groups, and C 1 -C 2 haloalkoxyl groups; and

each R a is independently chosen from hydrogen and C 1 -C 2 alkyl groups; and

R 7 is chosen from hydrogen, halogens, a cyano group, and C 3 -C 10 cycloalkyl groups optionally substituted with one or more groups chosen from C 1 -C 2 alkyl groups, C 1 -C 2 haloalkyl groups, and halogens;

q is 1, 2, 3 or 4; and

Z is a divalent linker of formula (L) r , wherein:

r is 1, 2, 3, 4, 5, or 6;

each L is independently chosen from C(R 8 )(R 9 ) groups, —O—, and —NR b — groups, wherein a heteroatom in Z is not bonded to another heteroatom in Z, wherein:

each R 8 and R 9 is independently chosen from hydrogen, halogens, C 1 -C 2 haloalkyl groups, C 1 -C 2 alkyl groups, a hydroxyl group, C 1 -C 2 alkoxyl groups, and C 1 -C 2 haloalkoxyl groups; and

each R b is independently chosen from hydrogen and C 1 -C 2 alkyl groups;

to form a compound of Formula (I), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.

17 .- 19 . (canceled)

20 . A method of preparing a compound of Formula (I)

a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein Ring D is

comprising

reacting a compound of Formula (X), a salt thereof, or a deuterated derivative of any of the foregoing, with a compound of Formula (Z-1), a salt thereof, or a deuterated derivative of any of the foregoing:

wherein:

Q a is a halogen;